TBI remained significantly associated with reduced adjusted risks of grade 3 to 4 aGVHD and moderate-severe cGVHD.

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced today that Dr. John C. Byrd, M.D., has joined its scientific advisory board (SAB). Byrd is an ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

Pirtobrutinib (brand name Jaypirca) could reduce progression or death risk by 46% in patients with chronic lymphocytic ...

EXCLUSIVE: When Kevin Davies saw volunteers swabbing concert goers for the stem cell register, he never dreamed he'd be a match for a desperate cancer sufferer in Germany.

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like ...